FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

10 results

abiraterone
(Abiraterone acetate)
CivicaScript, LLC
Usage: Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer (CRPC) and metastatic high-risk castration-sensitive prostate cancer (CSPC).
abiraterone acetate
(abiraterone acetate)
Novugen Pharma (USA) LLC
Usage: Abiraterone acetate tablets are indicated, in combination with prednisone, for the treatment of metastatic castration-resistant prostate cancer (CRPC) and metastatic high-risk castration-sensitive prostate cancer (CSPC).
abiraterone acetate
(Abiraterone)
AvKARE
Usage: Abiraterone acetate tablets, in combination with prednisone, are indicated for the treatment of metastatic castration-resistant prostate cancer (CRPC).
akeega
(NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE)
Janssen Biotech, Inc.
Usage: AKEEGA, in combination with prednisone, is indicated for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Treatment selection should be based on an FDA-approved test for AKEEGA.
jevtana
(cabazitaxel)
Sanofi-Aventis U.S. LLC
Usage: JEVTANA® is indicated for use with prednisone in treating patients with metastatic castration-resistant prostate cancer who have previously undergone treatment with a docetaxel-containing regimen.
rubraca
(rucaparib)
Clovis Oncology, Inc.
Usage: Rubraca is indicated for maintenance treatment of adult patients with BRCA-mutated recurrent ovarian, fallopian tube, or primary peritoneal cancer responding to platinum-based chemotherapy, and for treating BRCA-mutated metastatic castration-resistant prostate cancer after androgen receptor therapy and taxane chemotherapy.
rubraca
(rucaparib)
pharmaand GmbH
Usage: Rubraca is indicated for the maintenance treatment of adults with BRCA-mutated recurrent ovarian cancer in response to platinum-based chemotherapy, and for treating BRCA-mutated metastatic castration-resistant prostate cancer after previous treatments. Selection for therapy should be guided by an FDA-approved companion diagnostic.
talzenna
(talazoparib)
Pfizer Laboratories Div Pfizer Inc
Usage: TALZENNA is indicated for treating adult patients with BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. It is also used in combination with enzalutamide for patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
yonsa
(abiraterone acetate)
Sun Pharmaceutical Industries, Inc.
Usage: YONSA is indicated for use in combination with methylprednisolone to treat patients with metastatic castration-resistant prostate cancer.
zytiga
(abiraterone acetate)
Janssen Biotech, Inc.
Usage: ZYTIGA is indicated for the treatment of metastatic castration-resistant prostate cancer (CRPC) and metastatic high-risk castration-sensitive prostate cancer (CSPC) when used in combination with prednisone.

Medications for Metastatic Castrationresistant Prostate Cancer

abiraterone

abiraterone acetate

abiraterone acetate

akeega

jevtana

rubraca

rubraca

talzenna

yonsa

zytiga